Kleo Brings Small-Molecule Approach To IO With Three Technological Applications
Emerging Company Profile: Using IP licensed from Yale, Kleo is betting it can complement or replace existing immuno-oncology drugs, specifically Darzalex. In partnership with PeptiDream, it just unveiled its first candidate for clinical development.
You may also be interested in...
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Amgen sees the approval as a platform to expand blinatumomab into other hematologic malignancies using similar approaches.
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.